A joint research team in the Universities of Basrah, Al-Qadisiyah and the Ministry of Education obtained a patent on Preparing a new steroid derivative called Monoxorel as a candidate for treating Prostate Cancer of the two types PC3 and LNCaP-Al.
The joint patent aimed at preparing a new Steroid derivative and studying its biological effectiveness in prostate Cancers as an inhibitor to chromosomal cell division and called Antimitotic Activity.
The joint patent, in which granted by the Central Organization for Standardization and Quality Control Unit of the Ministry of Planning, took more than two years of work in the laboratories of Basrah University and Al-Qadisiyah University.
The joint patent revealed that the prepared compound showed a higher anti-cell fission activity compared to the drug Colchicine.
It is worth mentioning that the joint research team included the faculty members in the University of Basrah Dr.Wasfi Abood Al-Masoudi, Dr. Zainab AbdulWahb Shehab from the College of Veterinary Medicine and Dr. Najm Abood Al-Masoudi from the College of Science, and the faculty member in the University of Al-Qadisiyah Dr. Nabil Abd AbdulRedha, and the researcher Mr. Ali Mahdi Farhan from the Ministry of Education.
